This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: pulmonary circulation

July 2021 Br J Cardiol 2021;28(3) doi:10.5837/bjc.2021.032 Online First

Real-world experience of selexipag titration in pulmonary arterial hypertension

Sarah Cullivan, Anandan Natarajan, Niamh Boyle, Ciara McCormack, Sean Gaine, Brian McCullagh

Abstract

Introduction Pulmonary arterial hypertension (PAH) is a devastating disease characterised by irreversible pulmonary vascular proliferation and remodelling, resulting ultimately in right heart failure. Current therapy targets the nitric oxide, endothelin and prostacyclin pathways to promote pulmonary vasodilatation and reduce right ventricular afterload.1,2 Selexipag is an oral selective prostacyclin-receptor agonist that is used in the treatment of PAH. In the GRIPHON (Prostacyclin [PGI2] Receptor Agonist In Pulmonary Arterial Hypertension) trial the optimum dose of selexipag for maximum therapeutic benefit frequently differed between individ

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now